Pfizer (PFE) Cash from Operations (2009 - 2026)

Pfizer (PFE) has 18 years of Cash from Operations data on file, last reported at 2615000000.0 in Q1 2026.

• Cash from Operations for Q1 2026 came in at 2615000000.0, up 11.99% year-over-year; the trailing twelve-month figure through Mar 2026 was 11984000000.0 (up 56.31% YoY), and the FY2025 annual result was 11704000000.0, down 8.16% from the prior year.
• Cash from Operations fell to 2615000000.0 in Q1 2026 per PFE's latest filing, from 5348000000.0 in the prior quarter.
• Over five years, Cash from Operations peaked at 20685000000.0 in Q4 2022 and troughed at 1781000000.0 in Q2 2024.
• A 5-year average of 4249800000.0 and a median of 3456000000.0 in 2023 frame the typical range for Cash from Operations.
• The sharpest annual moves came in 2023 and 2025: Cash from Operations tumbled 114.79% in 2023, then surged 114.22% in 2025.
• A 5-year view of Cash from Operations shows it stood at 20685000000.0 in 2022, then plunged by 74.67% to 5240000000.0 in 2023, then rose by 14.94% to 6023000000.0 in 2024, then decreased by 11.21% to 5348000000.0 in 2025, then tumbled by 51.1% to 2615000000.0 in 2026.
• Business Quant data shows PFE's Cash from Operations at 2615000000.0 in Q1 2026, 5348000000.0 in Q4 2025, and 4603000000.0 in Q3 2025.